• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK Archive

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view current FDA-TRACK performance measures and projects view the Active Index

Filter








Results

Number of results: 42

ItemProgramOfficeFY
Completed
Strategic PlanStrategic Goal/Area
1Percentage of international meeting requests received by CVM from others and that are held at CVM on a monthly basisCVMOffice of the Center Director2014N/AN/A
2Percentage of meeting requests received by CVM from others and that are held/hosted by others on a monthly basisCVMOffice of the Center Director2014N/AN/A
3Percentage of bilateral meetings conducted in the quarterCVMOffice of the Center Director2014N/AN/A
4Percentage of trilateral meetings conducted in the quarterCVMOffice of the Center Director2014N/AN/A
5Percentage of WTO SPS notifications commented on within 15 days of date assignedCVMOffice of the Center Director2014N/AN/A
6Percentage of PMAPs established for new CVM employees completed on-time, within 30 days of arrival, during the monthCVMOffice of Management2014N/AN/A
7Strategic Human Capital Plan ProjectCVMOffice of Management2011N/AN/A
8Resource Planning for Foods Program ProjectCVMOffice of Management2011N/AN/A
9Total number of training events offered during the monthCVMOffice of Management2010N/AN/A
10Total percentage of OM employees who attended training events during the monthCVMOffice of Management2010N/AN/A
11Percentage of CVM employees who reported 100% of their time during the reporting periodCVMOffice of Management2010N/AN/A
12Competency Models ProjectCVMOffice of Management2010N/AN/A
13Workforce Initiative Planning Strategies Project - Workforce ProfilesCVMOffice of Management2010N/AN/A
14Workforce Initiative Planning Strategies Project - Attrition Projection ModelsCVMOffice of Management2010N/AN/A
15Pioneer and Generic Animal Drug User Fees RenegotiationsCVMOffice of Management2013N/AN/A
16Percentage of designation submissions reviewed and acted on within 100 daysCVMOffice of Minor Use and Minor Species Animal Drug Development2014N/AN/A
17Percentage of INAD study submissions reviewed within the month that were acted on within 180 days after the submission dateCVMOffice of New Animal Drug Evaluation2014N/AN/A
18Percentage of INAD submissions consisting of protocols without substantial data reviewed and acted on within the month where the sponsor was notified of the Agency's decision on or before day 50CVMOffice of New Animal Drug Evaluation2014N/AN/A
19Percentage of manufacturing supplemental new animal drug applications and reactivations of such supplemental applications reviewed within the month that were acted on within 120 days after the submission dateCVMOffice of New Animal Drug Evaluation2014N/AN/A
20Percentage of non-administrative original ANADAs and reactivations of such applications completed on timeCVMOffice of New Animal Drug Evaluation2014N/AN/A
21Percentage of manufacturing supplemental ANADAs and reactivations of such supplemental applications completed on timeCVMOffice of New Animal Drug Evaluation2014N/AN/A
22Percentage of JINAD study submissions completed on timeCVMOffice of New Animal Drug Evaluation2014N/AN/A
23Percentage of JINAD submissions consisting of protocols without substanial data completed on timeCVMOffice of New Animal Drug Evaluation2014N/AN/A
24Percentage of administrative ANADAs (ANADAs submitted after all scientific decisions have been made in the JINAD process) completed on timeCVMOffice of New Animal Drug Evaluation2014N/AN/A
25Number of pre-AGDUFA generic new animal drug submissions reviewed and completed during the monthCVMOffice of New Animal Drug Evaluation2010N/AN/A
26Number of pending pre-AGDUFA submissions to review at the end of the monthCVMOffice of New Animal Drug Evaluation2010N/AN/A
27Nanotechnology Project - Develop Policies and ProceduresCVMOffice of New Animal Drug Evaluation2010N/AN/A
28Total number of training events offered during the monthCVMOffice of New Animal Drug Evaluation and Office of Minor Use and Minor Species Animal Drug Development2010N/AN/A
29Total percentage of ONADE and OMUMS employees who attended training events during the monthCVMOffice of New Animal Drug Evaluation and Office of Minor Use and Minor Species Animal Drug Development2010N/AN/A
30Linkages between Gene and Protein Expression and Chemical Exposures Measures - Determine the impact of canine MDR-1 mutations on therapeutic effectiveness and adverse reactions to veterinary drugsCVMOffice of Research2014N/AN/A
31Integrated Techniques, Approaches, and Technologies for the Characterization of Genomic and Proteomic Biomarkers Measures – Development of techniques to analyze biological specimens for biomarkers of disease or therapeutic responseCVMOffice of Research2013N/AN/A
32NARMS Measures - Develop better molecular techniques for the characterization of isolates in foodborne pathogensCVMOffice of Research2014N/AN/A
33NARMS Data Management Systems ProjectCVMOffice of Research2012N/AN/A
34Updating Obsolete Regulatory Residue Methods ProjectCVMOffice of Research2014N/AN/A
35Total number of training events offered during the monthCVMOffice of Research2010N/AN/A
36Total percentage of OR employees who attended training events during the monthCVMOffice of Research2010N/AN/A
37Average number of business days for CVM to complete the review of warning letters from ORA districts and number of OSC staff reviewing warning letters during the monthCVMOffice of Surveillance and Compliance2014N/AN/A
38ADE Reports System ProjectCVMOffice of Surveillance and Compliance2010N/AN/A
39MNVP ProjectCVMOffice of Surveillance and Compliance2012N/AN/A
40Development of XML Files for Releasable CVM ADE DataCVMOffice of Surveillance and Compliance2014N/AN/A
41Total number of training events during the monthCVMOffice of Surveillance and Compliance2010N/AN/A
42Total percentage of OSC employees who attended training events during the monthCVMOffice of Surveillance and Compliance2010N/AN/A

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.